phocyte infusions (15) . Retaining the GVL effect while eliminating GVHD has been an elusive clinical goal. Additional testing is needed to determine whether CD44 + CD62L -CD4 + effector memory T cells might retain GVL activity, and whether specific immunization strategies of the donor might enhance transfer of protective immunity and GVL.
Translation to clinical testing
Finally, as pointed out by the authors (5) , "if these murine results are applicable to human alloSCT, selective administration of memory T cells could greatly improve post-transplant immune reconstitution." Before this is attempted clinically, murine CD44 + CD62L --CD4 + effector memory T cells still need to be tested in other strain combinations, evaluated for transfer of protective immunity, and tested for GVL potential. In addition, the immune capabilities of human CD44 + CD62L --CD4 + effector memory T cells must be studied in vitro and in adoptive transfer models (i.e., in immunodeficient or humanized mice) to determine whether their behavior parallels that of murine CD44 + CD62L -CD4 + T cells.
There is still much to do before we can forget about GVHD. 
Preventing pathological regression of blood vessels
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Oxygen administration to premature infants suppresses retinal VEGF expression and results in the catastrophic vessel loss associated with retinopathy of prematurity. A study investigating the development of the retinal vasculature in mice (see related article on pages 50-57) demonstrates that specific activation of VEGF receptor-1 by placental growth factor-1 protects against oxygen-induced vessel loss without stimulating vascular proliferation and neovascularization.
A number of human disorders are associated with obliteration of preexisting blood vessels. Microvessel rarefaction often takes place in the hypertensive lung, in the myocardium of patients with chronic renal failure, and in the elderly. Conversely, a failure to eliminate transient embryonic vasculature destined for regression may lead to a disease, as exemplified by the common congenital developmental anomaly of the eye, persistent hyperplastic primary vitreous, in which hyaloid vessels fail to regress. A striking example of a disease caused by vessel regression is retinopathy of prematurity (ROP). ROP is a blindness-causing neovascularizing disease that affects premature infants treated with high concentrations of oxygen. ROP develops in two distinct stages. First, the hyperoxic insult leads to obliteration of immature retinal vessels, thereby compromising retina perfusion. The second phase, initiated upon resumption of the breathing of normal air, is an adverse compensatory neovascularization response, mediated by ischemiainduced VEGF, in which formation of new vessels is excessive, neovessels are leaky, and the inner limiting membrane of the retina is breached, allowing vessel growth into the vitreous. The later event may ultimately lead to retinal detachment and vision loss.
Protecting retinal vessels from oxygen-induced obliteration
Why are newly formed blood vessels of the retina so vulnerable to excess oxygen? Vessel regression in ROP repre- (2) highlights an emerging role of PlGF-1 as a vascular survival factor. A vasoprotective effect of PlGF against oxygeninduced degeneration of retinal vessels was also reported by Upalakalin et al. (9) . Previously, the vasoprotective effect of PlGF was demonstrated in tumors (10) , and its activity as an autocrine survival factor for trophoblasts was also demonstrated (11) . Mechanistically, little is known regarding the signal transduction pathways that culminate in vasoprotection. In the case of the pro-survival signals elicited by VEGF, a phosphorylation of the survival kinase Akt1 and the functional significance of this reaction in inhibiting endothelial cell apoptosis have been demonstrated (12, 13) . Additionally, VEGF was shown to sents an exaggeration of an otherwise natural response to oxygen surplus. Normally, the tissue responds to excess oxygen by trimming its microvasculature to the extent that oxygen supply is reset to match the metabolic requirements of the tissue. However, the vast excess of iatrogenic oxygen is misinterpreted and results in overpruning of the newly formed vascular tree. The process is mediated by VEGF acting as a vascular survival factor. Specifically, suppression of VEGF expression by hyperoxia to levels below those required for maintaining immature vessels leads to endothelial cell apoptosis (1) . It was further demonstrated that vessels can indeed be rescued by exogenous VEGF compensating for the diminution of endogenous VEGF, suggesting that VEGF might be used therapeutically for preventing vessel regression in ROP (1). This proposition seemed counterintuitive, however, as VEGF is also the factor that stimulates abnormal vessel proliferation in ROP and, furthermore, VEGF might induce vascular leaks. In this issue of the JCI, Shih and coworkers have circumvented these concerns by using an agonist that exclusively activates the VEGF receptor-1 (VEGFR-1, also known as Flt-1) namely, the placental growth factor-1 (PlGF-1) (2). The authors show that PlGF-1 protects neonatal retina vessels from hyperoxia-induced obliteration without provoking retinal neovascularization or edema (2) (Figure 1 ). upregulate expression of antiapoptotic genes like the caspase inhibitor survivin, and Bcl-2 (14, 15) . For PlGF, the stress-activated protein kinase, JNK, and P38 kinase pathways were shown to be activated in trophoblasts, while the extracellular signal-regulated kinase-1 (ERK-1) and ERK-2 pathways were activated in endothelial cells (11) . Also, PlGF was shown to specifically upregulate survivin (10) .
Prospects of vessel-stabilization therapy
What are the prospects of harnessing vessel-stabilizing agents for therapy? Clearly, the case of ROP is unique, considering the defined nature of the pathogenic insult, its relatively short duration (unlike in the chronic cases of vessel rarefaction, vessels in ROP need to be protected only during the period spent in the oxygen chamber), and its predetermined onset. These characteristics, in conjunction with the facts that the vitreous is a close, immunoprivileged compartment and that the superficial retinal vessels are accessible to injected reagents, increase the likelihood of success. An alternative approach to growth factor administration is the use of mimetics that activate the relevant signal transduction pathways. This, however, must await further mechanistic insights on transduction of pro-survival signals. ROP is different from other pathologies of abnormal vessel regression in that the vessels eliminated are immature and hence VEGF dependent. Immaturity of vessels in expanding tumors may also be exploited for enforcing vessel regression via a VEGF withdrawal strategy (16) . There are no clues, however, on how the rarefaction of mature vessels that are refractory to VEGF might be prevented.
